NCT03495609View on ClinicalTrials.gov

Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers

PHASE4CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 17, 2016

Primary Completion Date

December 18, 2018

Study Completion Date

December 18, 2018

Conditions
hCGBRCA1 MutationBRCA2 Mutation
Interventions
DRUG

Ovitrelle

Ovitrelle will be injected in 35 asymptomatic women with BRCA1 or BRCA2 mutation during 90 days (an extra 4 weeks in a subgroup). The gene expression of the breast epithelial cells will be characterized and compared to the gene expression of the breast epithelial cells before ovitrelle injection.

Trial Locations (1)

9000

Ghent University Hospital, Ghent

All Listed Sponsors
collaborator

Fox Chase Cancer Center

OTHER

collaborator

Ziekenhuis Oost-Limburg

OTHER

lead

University Hospital, Ghent

OTHER

NCT03495609 - Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers | Biotech Hunter | Biotech Hunter